WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Regulation FD Disclosure

WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Item 7.01 Financial Statements and Exhibits.
Story continues below

(d) Exhibits.

The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed:


Wave Life Sciences Ltd. Exhibit
EX-99.1 2 d559862dex991.htm EX-99.1 EX-99.1 Wave Life Sciences Corporate Presentation March 26,…
To view the full exhibit click here

About WAVE LIFE SCIENCES LTD. (NASDAQ:WVE)

WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington’s disease, duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD). In Huntington’s disease, it has programs that target HTT SNP-1 and HTT SNP-2; in DMD, it targets Exon 51, and in IBD, it targets SMAD7. It has selected lead product candidates in its programs targeting HTT SNP-1 and Exon 51. It has late-stage discovery programs in epidermolysis bullosa simplex, in which it targets KRT14 SNP-1 and KRT14 SNP-2, and in DMD, in which it is focused on an additional DMD target, AcRIIb.

An ad to help with our costs